Table 2 Treatment modalities of participants in RAMP-DM group and usual care group at baseline and 12Â months
|  | RAMP-DM (N = 1072) | Usual care (N = 1072) |  |
|---|---|---|---|
| Â | n(%) | P-valuea | |
Treatment Modalities at baseline | |||
On oral glucose-lowering drugs | 949 (88.5%) | 941 (87.8%) | 0.593 |
On insulin | 17 (1.59%) | 76 (7.1%) | <0.001 |
On anti-hypertensive drugs | 835 (77.9%) | 818 (76.3%) | 0.382 |
On lipid-lowering drugs | 866 (80.8%) | 880 (82.1%) | 0.437 |
Treatment Modalities at 12Â months | |||
On oral glucose-lowering drugs | 967 (90.2%) | 949 (88.5%) | 0.207 |
On insulin | 63 (5.9%) | 115 (10.7%) | <0.001 |
On anti-hypertensive drugs | 871 (81.3%) | 852 (79.5%) | 0.302 |
On lipid-lowering drugs | 935 (87.2%) | 949 (88.5%) | 0.354 |
Enrolled in PEP | 77 (7.2%) | 28 (2.6%) | <0.001 |
Receiving nurse assessment | 1072 (100%) | -- | -- |
Receiving nurse intervention | 766 420 (39.2%) | -- | -- |
Receiving associate consultant intervention | 143 (13.3%) | -- | -- |
Receiving allied health professionals intervention | 190 (17.8%) | 12 (1.1%) | <0.001 |